Delivery Order SPE2DB20D1100-SPE2DB25FE6U5
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Lisdexamfetamine 30 mg capsules (100-count units) on September 3, 2025, with a ceiling value of $1,176.88 and ultimate completion date of September 4, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract represents a child award under a larger...
- The Defense Logistics Agency awarded a $10,066.22 delivery order to AmerisourceBergen Drug Corp on September 18, 2025, for the supply of Lisdexamfetamine 20 mg capsules (90-count units). This is a firm fixed-price delivery order with an ultimate completion date of September 19, 2025, and represents a non-competitive set-aside contract. The product will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its primary...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 16, 2025, for the supply of Lisdexamfetamine 20 mg capsules (90-count units) with a ceiling value of $1,050.75. This competitively awarded, firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999.99 million through December 2026. The contract utilizes no set-aside...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Lisdexamfetamine 20 mg capsules (100 count) on August 28, 2025, with a ceiling value of $1,726.50 and a completion date of August 29, 2025. This competitively awarded, firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which is valued at $999.9 million and extends through December...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 11, 2025, for the supply of Lisdexamfetamine 30 mg capsules (100-count units) with a ceiling value of $6,184.82. This is a firm fixed-price delivery order with no set-aside designation, issued under competitive procurement procedures. The contract is scheduled for ultimate completion on September 12, 2025, with performance taking place at AmerisourceBergen's facility in Conshohocken, Pennsylvania....
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 12, 2025, for the supply of Lisdexamfetamine 50 mg capsules (90-count units) valued at $1,057.44. This is a firm fixed-price delivery order with no set-aside designation, reflecting competitive award practices. The delivery order is due for completion by September 15, 2025, and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order represents a child...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 8, 2025, for the supply of Lisdexamfetamine 50 mg capsules (100-count units) with a ceiling value of $1,651.64. This competitively awarded, firm fixed-price delivery order is set to be completed by September 9, 2025, and will be performed at AmerisourceBergen's corporate offices in Conshohocken, Pennsylvania. The award represents a child order under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a delivery order valued at $3,957.98 to AmerisourceBergen Drug Corp for Lisdexamfetamine 20 mg capsules (100 count) on September 8, 2025, with completion targeted for September 9, 2025. This non-set-aside, competitively awarded contract employs firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger pharmaceutical supply vehicle with DLA. The pharmaceutical product will be delivered to the vendor's corporate office location...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 24, 2025, for Lisdexamfetamine 20 mg capsules (100-count units) with a ceiling value of $2,587.33. This is a firm fixed-price delivery order with no set-aside designation, indicating competitive award through open competition. The order is set to complete by July 25, 2025, with performance taking place at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 29, 2025, for the supply of Lisdexamfetamine 20 mg capsules (100-count units) under a firm fixed-price contract valued at $11,279.96. This non-competitive delivery order is expected to be completed by September 2, 2025, with performance occurring at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The award represents a child contract under the company's larger Indefinite Delivery...
- SPE2DB20D1100Indefinite Delivery Contract
- SPE2DB20D1100-SPE2DB25FE6U5Delivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 15, 2025, for the supply of Lisdexamfetamine 20 mg capsules (90-count units) with a ceiling value of $11,578.87. This firm fixed-price delivery order, with an ultimate completion date of September 16, 2025, represents a non-competitive set-aside arrangement and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract falls under AmerisourceBergen's broader pharmaceutical supply relationship with the Defense Logistics Agency, supporting federal medical procurement needs for military and veteran healthcare systems. This delivery order is a child contract issued under AmerisourceBergen Drug Corp's substantial Indefinite Delivery Contract (SPE2DX) with DLA Troop Support Medical, valued at $999,999,999.00 through December 2026. The parent IDC serves as a comprehensive global pharmaceutical support vehicle enabling AmerisourceBergen to supply a vast range of medications, vaccines, and medical supplies to support military healthcare programs worldwide. Lisdexamfetamine, a controlled stimulant medication used primarily for attention-deficit/hyperactivity disorder treatment, represents the type of specialized pharmaceutical commodity within the broader therapeutic domains covered under this strategic contract vehicle supporting the Defense Health Agency and other government healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $11.6k | 9/15/25 |